Clinicians Split On Warfarin Gene Testing As A New Standard Of Care

FDA's drug and device centers are increasingly putting their weight behind the use of genetic tests to determine proper dosing of the anti-clotting drug warfarin, but convincing doctors is proving a bigger challenge